When H. pylori Won't Go Away: A Patient's Guide to Refractory Infection and Treatment Options

Table of Contents

• Key Points
• Background: Why H. pylori Infection Matters
• What Does "Refractory" Mean?
• Why Does H. pylori Treatment Fail?
• Antibiotic Resistance: The Leading Cause
• Nonadherence: Taking Medications Correctly
• Acid Suppression and Host Genetics
• Other Host Factors and Bacterial Diversity
• The 12 Best Practice Recommendations at a Glance
• Treatment Options After the First Failure
• Clinical Implications and What This Means for Patients
• Study Limitations
• Frequently Asked Questions
• Source Information

Key Points

• Antibiotic resistance and not taking medications as prescribed are the main causes of refractory H. pylori infection.
• If you previously took clarithromycin or levofloxacin, those drugs should usually be avoided because resistance is likely.
• Taking the full 14-day course, not skipping doses, and getting enough stomach acid suppression improve eradication success.
• After two failed treatments with confirmed adherence, ask your doctor about H. pylori susceptibility testing.
• Amoxicillin, tetracycline, and rifabutin resistance are rare, so they remain possible treatment options.

Background: Why H. pylori Infection Matters

H. pylori is recognized as one of the most common chronic bacterial infections in the world, infecting approximately half of the global population. The World Health Organization (WHO) has designated H. pylori as a carcinogen — a substance capable of causing cancer — and it is the strongest known risk factor for non-cardia gastric adenocarcinoma, the most common form of stomach cancer.

H. pylori is also causally linked to peptic ulcer disease (sores in the lining of the stomach or the first part of the small intestine).

While only 1% to 3% of infected individuals will ever develop malignant complications, the numbers are still striking. H. pylori accounts for 15% of the total cancer burden globally, and up to 89% of all gastric cancer cases are attributable to this single bacterium. Because of these risks, all major gastroenterological societies recommend that H. pylori be eradicated in anyone who tests positive.

When treatment fails, the consequences go beyond the persistent infection itself. Patients face repeated exposure to antibiotics and high-dose acid suppression, increased antibiotic resistance in both H. pylori and other bacteria, and added costs to the healthcare system. Critically, the likelihood of successful eradication decreases with each subsequent therapeutic attempt, which is why every effort should be made to address factors that might contribute to failure the first time — and to get it right the second time.

What Does "Refractory" Mean?

In this expert review, refractory H. pylori infection is defined as a persistently positive non-serologic H. pylori test result — meaning a breath test, stool test, or gastroscopy-based (endoscopy with biopsy) test — at least 4 weeks after completing one or more courses of a current guideline-recommended first-line eradication therapy. Importantly, the test must be done while the patient is off any medications that could affect test sensitivity, such as proton pump inhibitors (PPIs).

This condition should be distinguished from recurrent infection, where a test is initially negative after treatment but later becomes positive. Recurrence might result from ongoing exposure to infected family members. In that case, the best approach may be to test household members and treat those who test positive, rather than assuming the original treatment didn't work.

Why Does H. pylori Treatment Fail?

Failure to eradicate H. pylori results from a complex interaction of three groups of factors: host-related (your body's genetics and habits), microbial-related (the bacteria's own defenses), and systems-related (how healthcare is delivered).

The two most commonly cited reasons for eradication failure are antibiotic resistance and patient nonadherence (not taking medications as directed). However, because primary eradication failure still occurs even when the bacteria are confirmed sensitive to antibiotics and the patient took the medication faithfully, additional factors are clearly also at play — especially in refractory cases. That's why providers should attempt to identify all contributing causes before simply prescribing a different antibiotic.

Antibiotic Resistance: The Leading Cause

Resistance to several of the antibiotics commonly used to treat H. pylori has risen globally over the last 20 years. Rising rates have been linked to prior use of that specific antibiotic — or others within the same class — by the individual patient, as well as to widespread antibiotic consumption at the population level.

Predictably, eradication failure is much more likely when the regimen includes an antibiotic to which H. pylori demonstrates in vitro resistance (resistance shown in laboratory testing). Combining studies of both treatment-naïve (never treated) and refractory patients, researchers found:

• Clarithromycin resistance is associated with a 7.0-fold (95% CI, 5.2–9.3-fold) higher likelihood of treatment failure in regimens containing the drug.
• Levofloxacin resistance is associated with an 8.2-fold (95% CI, 3.8–17.6-fold) higher likelihood of failure.
• Nitroimidazole resistance (e.g., metronidazole) has a relatively smaller impact, increasing the odds of failure by 2.5-fold (95% CI, 1.8–3.5-fold).

In plain language: if the bacteria are resistant to clarithromycin, you are about 7 times more likely to fail treatment with that drug, and if resistant to levofloxacin, about 8 times more likely — numbers that are statistically significant (the confidence intervals tell us the true effect is likely within these ranges).

Importantly, selecting eradication therapy based on prior antibiotic exposure is not inferior to selecting therapy based on in vitro susceptibility testing. This is good news, because it bypasses the logistical barriers — time, cost, and limited availability — of obtaining culture-based testing.

How Common Is Resistance?

According to a comprehensive systematic review and meta-analysis of data from more than 50,000 patients across 45 countries, primary resistance rates (in patients never treated before) varied by global region as follows:

• Clarithromycin: 10% to 34%
• Levofloxacin: 11% to 30%
• Metronidazole: 23% to 56%

After unsuccessful treatment (secondary resistance), rates climbed even higher:

• Clarithromycin: 15% to 67%
• Levofloxacin: 19% to 30%
• Metronidazole: 30% to 65%

By contrast, resistance rates were low for amoxicillin and tetracycline — generally occurring in less than 5% of strains, usually in the 1% to 2% range. H. pylori also demonstrates low primary and secondary resistance to rifabutin based on other reports.

Resistance Rates in the United States

Estimating resistance rates in the U.S. is particularly challenging because measuring resistance is uncommon in everyday clinical practice, resulting in very limited contemporary data. However, a few key studies provide a snapshot:

• A prospective multicenter U.S. study of 347 strains collected from 1998 to 2002 found overall resistance rates (treatment-naïve and previously treated combined) of 13% for clarithromycin and 25% for metronidazole.
• In 128 strains cultured at the Houston Veterans Affairs Medical Center from 2009 to 2013, resistance rates among the 110 treatment-naïve patients were 15% for clarithromycin, 17% for metronidazole, and 29% for levofloxacin, with 15% of strains resistant to more than one antibiotic.
• Most recently, primary resistance rates in 345 strains collected during a multicenter clinical trial were 17% for clarithromycin and 44% for metronidazole.

One additional nuance: because H. pylori infection is most often acquired in childhood, immigrants from countries where H. pylori is endemic may carry strains with resistance patterns characteristic of their native country, not their host country. This underscores the need for better surveillance registries.

How Resistance Develops at the Genetic Level

The dominant molecular mechanisms responsible for antibiotic resistance in H. pylori are well established. Clarithromycin resistance usually results from one of three point mutations in the 23S ribosomal subunit. Levofloxacin resistance involves mutations in DNA gyrase subunit A. Amoxicillin resistance comes from mutations in penicillin-binding protein 1. Tetracycline resistance stems from mutations in the genes encoding the binding site for the ribosomal 16S subunit, or from increased drug efflux. Rifabutin resistance involves mutations in rpoB, the beta subunit of the RNA polymerase gene.

Nitroimidazole (metronidazole) resistance is more complicated, usually related to mutations within rdxA, a gene that encodes a nitroreductase normally responsible for activating the drug. The complexity of rdxA mutations — and possible synergy with other redox-associated genes — precludes simple molecular testing for clinical resistance profiling. Furthermore, culture-based (phenotypic) testing methods are not well standardized for metronidazole, which may explain its relatively low predictive value for treatment outcomes.

Nonadherence: Taking Medications Correctly

The exact level of adherence needed for successful eradication in refractory H. pylori isn't known, but studies show that taking more than 60% to more than 90% of the prescribed course might be sufficient for success in primary infection. The threshold likely varies depending on individual factors, and it may plausibly be higher for refractory H. pylori, which is why adherence deserves special attention after a failed attempt.

The statistics on communication are sobering: a national U.S. survey reported that only 38% of participating providers asked patients about prior antibiotic exposure before prescribing treatment. That leaves considerable room for improvement.

Common barriers to adherence include the complexity of eradication regimens (multiple drugs, multiple times per day), the associated high pill burden, physical intolerance of medications, poor provider communication, and an overall lack of understanding of why therapy is indicated. The authors urge providers to explore and address these barriers before prescribing — explaining the rationale for therapy, dosing instructions, expected adverse events, and the importance of completing the full treatment course.

Two recent large randomized controlled trials from China found that using an interactive smartphone medical app and text-based reminders during treatment improved adherence to primary therapy. These tools deserve further investigation in the U.S. for refractory infections, particularly to determine which approaches work best in different populations, based on age, race, ethnicity, educational level, access, and language. Old-fashioned aids like pillboxes, medication calendars, and pharmacist counseling may also help.

Acid Suppression and Host Genetics

Host genetics play a meaningful role in refractory H. pylori infection, particularly polymorphisms (natural genetic variations) that affect intragastric pH — the acidity level in your stomach.

Here's the key concept: H. pylori is most susceptible to antibiotics when the intragastric pH is consistently between 6 and 8, because that's the optimal pH range for the bacteria to replicate. Some antibiotics, including clarithromycin and amoxicillin, also require acid suppression for maximum efficacy and sustained activity.

The numbers illustrate this dramatically. At a gastric pH below 2 (very acidic), the half-lives of amoxicillin and clarithromycin are approximately 15.2 ± 0.3 hours and 1.0 ± 0.04 hours, respectively. At a gastric pH above 7, the half-lives of both antibiotics exceed 68 hours. In other words, without adequate and sustained acid suppression, H. pylori can survive exposure to antibiotics to which it is otherwise sensitive in the lab.

The largest body of research on host genetics focuses on CYP2C19, the liver enzyme responsible for metabolizing the earlier-generation proton pump inhibitors (PPIs) like omeprazole and lansoprazole. People with "poor metabolizer" CYP2C19 genotypes have high blood levels of PPIs, which is beneficial for acid suppression. People with "extensive metabolizer" (metabolism-enhancing) phenotypes clear the drugs quickly, which is associated with higher rates of eradication failure when CYP2C19-heavy PPIs are used.

There are important racial and ethnic differences in the U.S.:

• Caucasians, non-Hispanic African Americans, and Hispanics have a significantly higher prevalence (57% to 71%) of metabolism-enhancing CYP2C19 phenotypes compared with Asian American ethnic groups (45%).
• Asian Americans have the highest prevalence of the poor-metabolizer genotype.
• Caucasians with extensive metabolizer phenotypes may clear omeprazole even faster than some Asian ethnic groups with the same genotype, suggesting additional genetic or gene-environment interactions.

Despite these considerations, current data are insufficient to recommend routine genetic polymorphism testing to guide therapy selection for refractory infection. However, given the high prevalence of rapid-metabolizer genotypes in non-Asian groups, the authors suggest it may be reasonable to empirically choose strategies that achieve greater acid suppression — such as higher dosing, more frequent dosing, or more potent PPIs.

Other Host Factors and Bacterial Diversity

Beyond genetics, non-genetic host factors and lifestyle choices also affect treatment success. Age and smoking are both associated with eradication treatment failure; one meta-analysis found that patients who smoked had higher failure rates. Comorbid conditions such as obesity and diabetes may also play a role, and the authors note these are important areas for future research.

Additionally, H. pylori has a remarkably high level of strain-specific genetic diversity. Different strains use various microbial mechanisms to promote persistence: manipulating and evading the host immune response, altering the gastric environment, increasing bacterial load, and enhancing virulence. While certain genetic constituents of the bacteria (such as cytotoxin-associated gene A and vacuolating cytotoxin A) are well known, they haven't yet been leveraged clinically to manage refractory infection — but they deserve attention as targets for future approaches.

The 12 Best Practice Recommendations at a Glance

The review's core practical value comes from its 12 Best Practice Advice (BPA) statements. Here they are in patient-friendly language:

1. Look beyond antibiotic resistance. The usual cause of refractory infection is antibiotic resistance, but providers should also check for inadequate adherence and insufficient gastric acid suppression.
2. Review all prior antibiotics. If you've taken macrolides (like clarithromycin) or fluoroquinolones (like levofloxacin) in the past, regimens based on those drugs should be avoided — resistance is highly likely. Resistance to amoxicillin, tetracycline, and rifabutin is rare, so those remain options.
3. Address adherence barriers before prescribing. Eradication regimens are complex. Providers should explain why treatment is needed, how to take the medication, what side effects to expect, and why finishing the full course matters.
4. After bismuth quadruple therapy fails, have a shared decision-making conversation. Options include (a) levofloxacin- or rifabutin-based triple therapy with high-dose dual PPI-amoxicillin, or (b) an alternative bismuth-containing quadruple therapy.
5. When using metronidazole, dose it adequately. Consider 1.5 to 2 grams daily in divided doses, especially with bismuth therapy, because this may improve eradication success even when in vitro metronidazole resistance is present.
6. Reconsider "penicillin allergy" labels. Without a history of anaphylaxis, penicillin allergy testing should be considered so the allergy can be "delisted" and amoxicillin potentially used. Amoxicillin should be given at a daily dose of at least 2 grams, divided 3 or 4 times per day, to avoid low trough levels.
7. Maximize acid suppression. Inadequate stomach acid suppression is linked to eradication failure. High-dose and more potent PPIs, PPIs not metabolized by CYP2C19, or potassium-competitive acid blockers (if available) should be considered.
8. Treat for longer. Fourteen days beats 7 days. Longer treatment durations provide higher eradication success rates, and whenever appropriate, longer durations should be chosen for refractory infection.
9. Weigh the risks and benefits of further attempts. The potential benefits of eradication should be balanced against the side effects and inconvenience of repeated antibiotics and high-dose acid suppression — especially in vulnerable populations like the elderly.
10. Consider susceptibility testing after 2 failures. After 2 failed therapies with confirmed patient adherence, H. pylori susceptibility testing should be considered to guide the choice of subsequent regimens.
11. Compile local data. Tracking local eradication success rates for each regimen, along with patient demographics and prior antibiotic exposure, is important. This data should be made publicly available to guide treatment choices.
12. Treat adjunctive therapies as experimental. Proposed adjuncts like probiotics are of unproven benefit for refractory H. pylori and should be considered experimental at this time.

Treatment Options After the First Failure

The authors propose a treatment algorithm based on two factors: what initial therapy was used and whether true penicillin allergy exists.

Of all the regimens discussed, only PBMT (PPI + bismuth + metronidazole + tetracycline) is FDA-approved for refractory H. pylori infection in the United States. If a bismuth-based quadruple therapy failed as first-line treatment, shared decision-making should guide the choice between:

• A levofloxacin- or rifabutin-based triple therapy combined with high-dose dual PPI and amoxicillin
• An alternative bismuth-containing quadruple therapy

Because of rising levofloxacin resistance, this drug should not be considered unless the H. pylori strain is known to be sensitive, or unless local population resistance rates are known to be below 15% — analogous to the longstanding rule for clarithromycin use in triple therapies. Rifabutin, by contrast, can reasonably be used in a triple regimen without prior sensitivity testing, since rifabutin and amoxicillin resistance are rare.

A recent study showed that adding rifabutin to a high-dose amoxicillin-plus-PPI dual regimen significantly improves eradication rates. Although that study used the regimen as first-line therapy, it is reasonable to consider PAR (PPI + amoxicillin + rifabutin) with high-dose or high-potency PPI and amoxicillin 750 mg three times daily over high-dose dual therapy alone.

Clinical Implications and What This Means for Patients

This expert review carries several practical messages for patients who have failed one or more H. pylori treatments:

• Don't assume another antibiotic is automatically the answer. Your treatment history — every antibiotic you've ever taken — matters enormously. Bring a complete medication list to your appointment.
• Take the full course, exactly as prescribed. Skipping doses, stopping early due to side effects, or taking pills at the wrong time can doom an otherwise effective regimen. Ask for help if you're struggling: pillboxes, alarms, apps, or pharmacist counseling all may help.
• Acid suppression is your partner. The goal is to keep your stomach pH in the range where the bacteria are vulnerable. Ask your doctor whether you're on the most effective PPI, at the right dose and frequency.
• Longer is usually better. If your doctor offers a 14-day course, take the full 14 days. Shorter courses fail more often.
• Advocate for susceptibility testing after 2 failures. If you've completed two full, adherent courses and still test positive, ask whether the bacteria can be cultured and tested for antibiotic sensitivities.
• Shared decision-making matters. Especially if you're older or have other health conditions, the decision to pursue another eradication attempt should weigh potential benefits against the real burden of more antibiotics and high-dose acid suppression.

The bigger systemic picture: the review calls for H. pylori eradication surveillance registries, wider access to antibiotic sensitivity testing, and less practice variability among providers. Better-localized data on resistance patterns would help everyone — doctors and patients alike — choose the right regimen the first time.

Study Limitations

It's important to understand the limits of this guidance:

• This is an expert review, not a formal systematic review, so no rating of the strength or quality of evidence was carried out.
• Recommendations combine available evidence with consensus-based expert opinion, which means some advice reflects the authors' clinical judgment rather than randomized trial data.
• Many of the studies cited were conducted in populations that are geographically and ethnically homogenous — often Asian-Pacific populations — which may not translate perfectly to the diverse U.S. population.
• There is a notable lack of recent comparative clinical trials in the U.S., limited knowledge of locoregional resistance patterns, and limited data on how host genetics play out in American patients.

Frequently Asked Questions

What does it mean if my H. pylori infection is called "refractory"?

Refractory means you still test positive for H. pylori at least 4 weeks after finishing a recommended first-line treatment. The test must be a breath, stool, or biopsy test, while you are off medicines like proton pump inhibitors. This is different from a new infection after successful treatment.

Why might my H. pylori infection not go away after treatment?

The most common reasons are antibiotic resistance and not taking medications exactly as prescribed. Other factors include insufficient stomach acid suppression, smoking, and host genetics. Even with correct antibiotic choice and good adherence, some infections still persist, so your doctor should look for all contributing factors before prescribing a different antibiotic.

I failed one round of H. pylori treatment. What are my options?

Your doctor will review every antibiotic you have taken, especially macrolides or fluoroquinolones, because resistance is likely. Options may include bismuth quadruple therapy, a levofloxacin- or rifabutin-based triple therapy, or high-dose dual therapy with a PPI and amoxicillin. The choice depends on your history, penicillin allergy status, and shared decision-making.

How common is antibiotic resistance in H. pylori?

In patients never treated before, resistance rates vary by region: clarithromycin 10-34%, levofloxacin 11-30%, and metronidazole 23-56%. After failed treatment, rates rise to 15-67% for clarithromycin, 19-30% for levofloxacin, and 30-65% for metronidazole. Resistance to amoxicillin, tetracycline, and rifabutin is generally low, under 5% for amoxicillin and tetracycline.

I have a penicillin allergy label. Can I still be treated for H. pylori?

If you have never had a severe allergic reaction like anaphylaxis, your doctor may recommend penicillin allergy testing to remove this label. Amoxicillin is a useful option, given at least 2 grams per day in divided doses. If true penicillin allergy exists, other regimens like bismuth quadruple therapy can be used.

What should I ask my doctor after two H. pylori treatment failures?

Ask whether H. pylori susceptibility testing can be done to guide the next antibiotic choice. Confirm that you took all medications correctly and that acid suppression was adequate. Also discuss the risks and benefits of another attempt, because success rates decrease with each round and repeated antibiotics have side effects.

Source Information

Original article title: Update on the Management of Refractory Helicobacter pylori Infection

Authors: Shailja C. Shah, Prasad G. Iyer, and Steven F. Moss

Publication: Gastroenterology, 2021;160:1831–1841 (published by the AGA Institute)

DOI: https://doi.org/10.1053/j.gastro.2020.11.059

This patient-friendly article is based on peer-reviewed research published in a major gastroenterology journal. It is intended for educational purposes and does not replace individualized medical advice from your healthcare provider. Always discuss your specific treatment plan with your doctor.